The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Overall survival (OS) of phase 3 CodeBreaK 300 study of sotorasib plus panitumumab (soto+pani) versus investigator’s choice of therapy for KRAS G12C-mutated metastatic colorectal cancer (mCRC).
 
Marwan Fakih
Honoraria - Amgen
Consulting or Advisory Role - Bayer; BMS; Eisai; Merck; Mirati Therapeutics; Pfizer; Roche/Genentech; Taiho Pharmaceutical
Research Funding - Agenus (Inst); Roche/Genentech (Inst); Verastem (Inst)
 
Lisa Salvatore
Honoraria - Amgen; AstraZeneca; Bayer; GlaxoSmithKline; Incyte; Merck Serono; MSD; Pierre Fabre; SERVIER; Takeda
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; GlaxoSmithKline; Incyte; Merck Serono; MSD; Pierre Fabre; SERVIER; Takeda
Research Funding - Merck Serono (Inst)
Travel, Accommodations, Expenses - Bayer; Merck Serono; Pierre Fabre; SERVIER
 
Taito Esaki
Honoraria - Chugai Pharma; Daiichi Sankyo; Taiho Pharmaceutical
Research Funding - Amgen (Inst); Amgen Astellas BioPharma (Inst); Asahi Kasei (Inst); Astellas Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); IQVIA (Inst); Jazz Pharmaceuticals (Inst); MSD (Inst); Nihonkayaku (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Quintiles (Inst); Syneos Health (Inst)
 
Dominik Paul Modest
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Cor2Ed; GlaxoSmithKline; Lilly; Merck; Merck Serono; Onkowissen; Pierre Fabre; Sanofi; Seagen; SERVIER; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen; Cor2Ed; GlaxoSmithKline; Lilly; Merck Serono; Onkowissen; Pierre Fabre; Regeneron; SERVIER; Takeda
Research Funding - Amgen (Inst); Servier (Inst)
Travel, Accommodations, Expenses - Amgen; Merck Serono; SERVIER
 
David Páez Lopez-Bravo
Consulting or Advisory Role - Amgen; Esteve
Speakers' Bureau - Amgen; MSD; Novartis
Travel, Accommodations, Expenses - Amgen; Ipsen; Lilly; Merck KGaA; Sanofi
 
Julien Taieb
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; BMS; Merck KGaA; MSD; Novartis; Pierre Fabre; Roche; SERVIER; takeda
Speakers' Bureau - Amgen; Merck; MSD; Pierre Fabre; SERVIER
 
Michalis Karamouzis
Honoraria - Astellas Pharma; BMS; MSD; Pfizer Hellas; Roche; SERVIER
Speakers' Bureau - BMSi
Travel, Accommodations, Expenses - Ipsen
 
Erika Ruiz-Garcia
Consulting or Advisory Role - Amgen; Astellas Pharma; Bayer; BMS; Merck Serono; Roche/Genentech
Travel, Accommodations, Expenses - Bayer; Gilead Sciences; Sanofi/Aventis
 
Tae Won Kim
Employment - Asan Medical Center
Research Funding - Genome Insight (Inst); Roche/Genentech (Inst)
 
Yasutoshi Kuboki
Honoraria - Lilly Japan; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Abbvie; Amgen; Boehringer Ingelheim; Incyte; Janssen Oncology; Takeda
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Carna Biosciences (Inst); Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Janssen Oncology (Inst); Jiangsu Hengrui Pharmaceuticals (Inst); Lilly (Inst); Merck Serono (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Amgen; Chugai Pharma; Incyte
 
Fausto Angelo Meriggi
No Relationships to Disclose
 
David Cunningham
Stock and Other Ownership Interests - OVIBIO
Consulting or Advisory Role - OVIBIO
Research Funding - 4SC (Inst); Bayer (Inst); Clovis Oncology (Inst); Leap Oncology (Inst); Lilly (Inst); MedImmune (Inst); Roche (Inst)
 
Kun-Huei Yeh
Honoraria - Amgen; Amgen; Boehringer Ingelheim; Bristol-Myers Squibb; Bristol-Myers Squibb; Daiichi Sankyo; Lilly; Merck; MSD; MSD Oncology; Novartis; Ono Pharmaceutical; Ono Pharmaceutical; Pfizer; Roche; Takeda; TTY Biopharm
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Daiichi Sankyo/Astra Zeneca; Daiichi Sankyo/Astra Zeneca; Lilly; MSD; MSD Oncology; Novartis; Ono Pharmaceutical; Ono Pharmaceutical; Roche; Takeda
Speakers' Bureau - Merck
 
Emily Chan
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Joseph Chao
Employment - Amgen
Stock and Other Ownership Interests - Amgen
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Guardant Health; Roche
Speakers' Bureau - Bristol Myers Squibb; Merck
Research Funding - Brooklyn Immunotherapeutics (Inst); Merck (Inst); Novonco Therapeutics (Inst)
Other Relationship - Daiichi Sankyo; Yiviva
 
Qui Tran
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Chiara Cremolini
Honoraria - Amgen; Bayer; Merck; Merck; MSD; Pierre Fabre; Roche; SERVIER
Consulting or Advisory Role - Amgen; Bayer; MSD; Nordic Bioscience; Pierre Fabre; Roche
Speakers' Bureau - Merck; Pierre Fabre; SERVIER
Research Funding - Bayer; Merck; Roche; SERVIER
 
Filippo Pietrantonio
Honoraria - Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi-Sankyo; Ipsen; Johnson&Johnson; Merck Serono; MSD Oncology; Pierre Fabre; Rottapharm Biotech; Seagen; SERVIER; Takeda
Consulting or Advisory Role - Amgen; Bayer; GlaxoSmithKline; Janssen; Merck Serono; MSD Oncology; Rottapharm Biotech; SERVIER; Takeda
Research Funding - Agenus (Inst); Amgen (Inst); Astrazeneca (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Lilly (Inst)
Travel, Accommodations, Expenses - Merck Serono; Pierre Fabre